Novel radionuclide agent delivers “striking” results in neuroendocrine tumors

Lutathera (lutetium Lu-177 dotatate) has demonstrated “quite striking” results with a favorable safety profile as a therapy for patients with progressive midgut neuroendocrine tumors (NETs) in the first randomized phase III study to evaluate a radiolabeled somatostatin analogue in this treatment setting, according to a leading researcher.

The latest results for the NETTER-1 study confirm earlier interim findings for the peptide receptor radionuclide therapy, a budding area of oncology research. Read more.